strengthen digit surgeri robot program
verb jv buy-out anoth reason like
anoth reason us get excit fundament reiter overweight rate share miss
upgrad see note last minut gift idea upgrad overw eight barclay
morn announc agreement acquir remain stake verb surgic surgic robot compani form
joint ventur ith verili life scienc alphabet compani overw eight cover internet media analyst
ross sandler acquisit expect close first half financi term ere disclos
 view transact posit believ verb surgic ill js effort digit surgery/robot earlier year
 acquir auri health billion cash front plu mileston also recent launch veli digit orthoped
 expect provid detail transact digit surgery/robot effort broadli investor
present januari confer call januari upcom medic devic consum day next year
question reach kristen
happi holiday
verb surgic
march googl first announc joint ventur develop next-gener surgic robot system
advanc tow ard digit surgeri verb surgic headquart silicon valley googl campu current
detail system develop limit compani identifi five key technolog pillar ill integr one
connect platform robot advanc instrument enhanc visual connect data analyt machin learn
 target launch said earn call focus come market quickli ould
rather make sure product differenti earn call manag note progress updat ill like
provid
juli verb surgic announc kurt azarbarzin join presid chief execut offic departur scott
huenneken ho serv ceo sinc compani found azarbarzin previous serv chief technolog
offic previous found surgiquest serv ceo compani
acquir also experi tyco healthcar covidien surgic understand ill
remain
invest robot digit surgeri
april close acquisit auri health billion cash plu billion milestone-rel conting
payment auri ork togeth pursu develop robot assist bronchoscop ablat
lesion lung compani enter cooper develop commerci agreement may ith
goal integr ethicon neuw ave flex microw ave ablat technolog system
auri monarch platform receiv fda clearanc march diagnost therapeut bronchoscopi procedur
monarch system cost approxim per robot pipelin monarch lung biopsi ell lung treatment via
ablat oncolyt virus addit compani look applic endourolog treatment kidney stone
 ell potenti applic gi endoscopi
februari acquir orthotaxi develop robot platform orthoped time acquisit compani
early-stag develop system total partial knee replac manag expect file approv
launch orthotaxi end american academi orthoped surgeon annual meet march think
march like competit standpoint robot design minim footprint requir pre-
oper imag comment price order magnitud cheaper competitor orthoped robot space
stryker mako zimmer biomet rosa time ill tell still plan
earlier month announc new digit surgeri platform orthoped introduc veli digit surgeri
platform compris innov four area patient solut optim surgic plan surgic implement
post-op monitor
 note today veli digit surgeri ill focu joint reconstruct includ exist technolog like kincis system
jointpoint system time plan add new technolog like robot solut patient select tool
advanc visual sensor app
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target reflect blend sum-of-the-part analysi averag histor rel pe basi
look across peer group relev stock sector current trade pharma devic consum use
ntm ep estim past year share trade premium market past year trade
premium market last year trade market multipl tw approach support price
target hich appli pe ep
risk may imped achiev barclay research valuat price nside risk greater pressur
biosimilars/gener increas pricing/reb advers litig rule pipelin failur competit product launch fda
action healthcar reform dilut deal integr issu upsid risk includ new product success success capit
deploy favor litig outcom competit product failur rotat defens stock
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
fd barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
